HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.

HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.

Optimizing HCV genotype 1 therapy in terms of response prediction and tailoring treatment is undoubtedly the cornerstone of treating HIV co-infected patients in clinical practice. Accordingly, our aim was to analyze the predictive value of HCV viral decline for sustained virological response (SVR),...

Full description

Bibliographic Details
Main Authors: Antonio Rivero-Juarez, Luis F López-Cortés, Angela Camacho, Almudena Torres-Cornejo, Ana Gordon, Rosa Ruiz-Valderas, Julian Torre-Cisneros, Juan A Pineda, Pompeyo Viciana, Antonio Rivero
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4063713?pdf=render

Internet

http://europepmc.org/articles/PMC4063713?pdf=render

Similar Items